Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01008917 · ClinicalTrials.gov registry record · Phase 1
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT01008917 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 25 participants.
The verdict
NCT01008917, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a Phase I study, which means that the goal is to see if the combination of Temsirolimus and Sorafenib is safe in patients with Hepatocellular Carcinoma. Sorafenib is a standard treatment for Hepatocellular Carcinoma. Temsirolimus is used to treat cancer in the kidneys. It is hoped that the addition of Temsirolimus will make Sorafenib more effective against Advanced Hepatocellular Carcinoma, however this can not be guaranteed. The addition of Temsirolimus to Sorafenib is not an FDA approved treatment for Advanced Hepatocellular cancer.
Interventions
- DRUG sorafenib with temsirolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2009-11-17 |
| Est. Completion | 2013-06-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01008917
The ClinicalTrials.gov registry entry for NCT01008917 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sorafenib with temsirolimus is the first listed.
NCT01008917 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01008917 about?
NCT01008917 is a clinical study titled "Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma". This is a Phase I study, which means that the goal is to see if the combination of Temsirolimus and Sorafenib is safe in patients with Hepatocellular Carcinoma. Sorafenib is a standard treatment for Hepatocellular Carcinoma. Temsirolimus is used to treat cancer in the kidneys. It is hoped that the a...
What is the current status of trial NCT01008917?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2009-11-17. Estimated completion is 2013-06-27.
What interventions are being tested in trial NCT01008917?
The interventions under investigation include: sorafenib with temsirolimus (DRUG).
Who is sponsoring clinical trial NCT01008917?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.